It highlights that patients with low eTILs are at higher risk of progression under immune checkpoint inhibition and that other options should be sought in these patients, i.e., BRAF/MEK inhibitors for BRAF-mutated melanoma, T cell therapies, and targeted therapy according to genomic alterations for BRAF wild-type melanoma. The gene discussed is BRAF; the disease is melanoma.